Phase II Study of Preoperative FOLFIRINOX Versus Gemcitabine/Nab-Paclitaxel in Patients With Resectable Pancreatic Cancer

NCT02243007 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

7

Enrollment

OTHER

Sponsor class

Stopped Slow Accrual

Conditions

Resectable Pancreatic Cancer
Pancreatic Ductal Carcinoma

Interventions

DRUG: FOLFIRINOX
DRUG: Gemcitabine/nab-Paclitaxel
RADIATION: Radiation therapy
DRUG: Capecitabine

Sponsor

Massachusetts General Hospital